New Long-term data evaluating BMS’ Cobenfy

Positive top-line results from the Phase III EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of Cobenfy (xanomeline and trospium chloride) in adults with schizophrenia over 52 weeks of treatment were presented at the 2024 Psych Congress, taking place from October 29 – November 2, 2024 in Boston, USA, said US pharma major Bristol Myers Squibb (NYSE: BMY).

“The results from our long-term trials further support the differentiated profile of Cobenfy and reinforce prior findings of robust and maintained symptom reduction with long-term treatment,” said Dr Alyssa Johnson, vice president and head of clinical development, Immunology, cardiovascular and neuroscience, Bristol Myers Squibb. “We’re pleased to see a compelling safety and tolerability profile associated with long-term Cobenfy treatment that is consistent with prior studies. Additionally, we continue to see a lack of weight gain, movement disorders, or metabolic changes with long-term use, reiterating the distinct profile and unique mechanism of action of Cobenfy. With Cobenfy now available for adults with schizophrenia, we look forward to further understanding the real-world impact of this differentiated treatment option,” Dr Johnson noted.

The US Food and Drug Administration approved (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults in September, making it is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors.